Stem cell & exosome therapy / Conditions hub
Stem cells & exosomes, indication by indication.
Cellular regeneration is not a single treatment for a single problem. It is a class of biologic protocols — applied to specific tissues, for specific patients, when the workup supports it. Below: the conditions we treat, organized by system, and what stem cell and exosome therapy actually does for each.
01The work
A class of biologics. Not a single product.
Stem cell therapy is shorthand. The cells we use are mesenchymal stem cells (MSCs) from screened, allogeneic sources — most commonly Wharton's-jelly tissue. Not embryonic. Not autologous fat or marrow aspirates. Not the unregulated material the FDA has issued warning letters about.
What MSCs do — at the level the literature supports — is modulate the local immune environment, signal to surrounding tissue, and release exosomes that drive paracrine repair. Exosomes are nanoscale signaling vesicles that can also be administered alone, with a different indication profile.
We deploy them in combination, in sequence, or alone — depending on the condition, the patient, and the workup. Imaging, labs, and functional assessment precede every protocol.
02 · IJoint & musculoskeletal
Joint, tendon, and soft-tissue work.
The largest and best-evidenced indication set. Targeted intra-articular and peri-tendinous protocols, often paired with diagnostics and adjunct modalities like Softwave shockwave.
-
01
Cartilage · joint
Knee osteoarthritis
The most common indication. Tibiofemoral or patellofemoral OA — alone or alongside physical therapy and load optimization.
Read the indication -
02
Cartilage · joint
Hip osteoarthritis
Image-guided intra-articular protocols for hip OA — most useful before joint-replacement candidacy or when surgery is contraindicated.
Read the indication -
03
Joint · tendon
Shoulder & rotator cuff
Rotator-cuff tendinopathy and partial-thickness tears, glenohumeral degeneration, and persistent pain not responding to PT.
Read the indication -
04
Joint · soft tissue
Ankle injuries & OA
Chronic ankle instability, post-sprain ligament dysfunction, and tibiotalar osteoarthritis — the most under-treated joint in regen.
Read the indication -
05
Joint · nerve
Wrist & hand arthritis
Thumb CMC arthritis, wrist OA, and carpal-tunnel-related nerve irritation — often the protocols patients delay longest.
Read the indication -
06
Spine · chronic pain
Chronic back & spine pain
Facet-mediated pain, disc-related symptoms, and post-procedural chronic pain. Imaging-led candidacy — never blind injection.
Read the indication -
07
Tendon · soft tissue
Tendinopathy
Tennis elbow, golfer's elbow, achilles tendinopathy, plantar fasciitis. Strong candidates for combined regen + shockwave.
Read the indication -
08
Sports · post-surgical
Sports & post-surgical recovery
Ligament injury (ACL, MCL), accelerated post-surgical healing, and return-to-sport protocols for athletes and active adults.
Read the indication
02 · IINeurological
Nerve & CNS recovery.
A more complex indication category — research is stronger for some conditions than others. We are explicit about the evidence base before recommending any protocol.
-
09
Nerve · recovery
Peripheral neuropathy
Diabetic and idiopathic peripheral neuropathy, post-injury nerve dysfunction. IV systemic plus targeted protocols.
Read the indication -
10
CNS · recovery
Stroke recovery
Post-ischemic recovery support with IV systemic protocols. Adjunctive to physical, occupational, and speech rehabilitation.
Read the indication -
11
Autoimmune CNS
Multiple sclerosis
Immune-modulating IV protocols for relapsing-remitting MS — used alongside (not in place of) disease-modifying therapy.
Read the indication -
12
Neurodegenerative
Parkinson's disease
IV systemic protocols for early-to-moderate Parkinson's. Adjunctive to neurology care — not a replacement for it.
Read the indication
02 · IIISystemic & internal medicine
Cardiovascular, renal, pulmonary, and metabolic.
Systemic IV protocols for chronic conditions where mesenchymal stem cell therapy has shown immune-modulating and tissue-supporting effects. Adjunctive — never a replacement for established care.
-
13
Cardiovascular
Heart disease & heart failure
IV protocols for ischemic and non-ischemic cardiomyopathy. Strict candidacy: stable patients, ongoing cardiology care.
Read the indication -
14
Renal
Chronic kidney disease
CKD stages 2–4. Immune-modulating IV protocols intended to slow progression — not reverse it. Coordinated with nephrology.
Read the indication -
15
Pulmonary
COPD
Chronic obstructive pulmonary disease — IV protocols targeting inflammation and tissue repair. Adjunct to pulmonology care.
Read the indication -
16
Endocrine
Diabetes
Type 2 diabetes and complications (neuropathy, slow wound healing). Systemic IV protocols, integrated with primary-care management.
Read the indication
02 · IVAutoimmune, sexual, aesthetic & longevity
The rest of what we treat.
Distinct indication profiles — autoimmune systemic protocols, exosome-led aesthetic and sexual-health applications, and longevity-oriented IV work.
-
17
Autoimmune · systemic
Autoimmune & chronic inflammation
Rheumatoid arthritis, lupus, psoriasis, IBD, and other systemic inflammatory conditions. Coordinated with rheumatology.
Read the indication -
18
Sexual · pelvic
Sexual health
ED, P-Shot, O-Shot — exosome and PRP protocols for men's and women's sexual and pelvic-health applications.
Read the indication -
19
Dermal · exosome-led
Hair restoration
Exosome-led protocols for androgenic alopecia and post-procedural hair loss. A focused, low-risk biologic application.
Read the indication -
20
Longevity · systemic
Performance & longevity
Systemic IV protocols for healthy adults pursuing measurable recovery, athletic performance, and longevity work.
Read the indication
03How a protocol begins
Workup first. Always.
Every stem cell or exosome protocol at Apex begins the same way: a 60–90 minute consultation, targeted imaging and labs chosen for the indication, and a written treatment plan that names the modality, dose, sequence, and follow-up cadence. We don't proceed without the data to justify the protocol — and we don't continue one that isn't producing the response we expected.